Inactive Instrument

News Bionomics Australian S.E.

Stocks

BNO

AU000000BNO5

Biotechnology & Medical Research

All News

07-23	Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million.	CI
07-23	Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell	MT
07-23	Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing	AQ
06-29	Neuphoria responds to the announcement made by London-listed Scancell Holdings plc	AQ
06-26	Neuphoria Confirms Business Combination Talks With Scancell	MT
06-26	Neuphoria Responds to the Announcement Made by London-Listed Scancell Holdings plc	CI
06-26	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc	AQ
06-26	Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria	CI
05-15	Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
02-18	Neuphoria Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-08	Neuphoria Therapeutics Inc. Announces Termination of Spyridon Papapetropoulos as CEO and Appointment as Interim CEO Effective December 31, 2025	CI
01-08	Neuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026	CI
12-18	Declaration of Voting Results by Neuphoria Therapeutics	CI
12-18	Neuphoria Therapeutics Inc. Approves Appointment of Stephen Doberstein and Kimberly Smith as Class I Directors for A Three-Year Term	CI
12-08	Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees	CI
12-08	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees	AQ
12-04	Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium	RE
12-04	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium	AQ
12-03	Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics	CI
12-03	Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement	CI
12-02	Neuphoria Therapeutics Issues a Statement in Response to Lynx1 Fictions	CI
12-01	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions	AQ
11-26	Lynx1 Capital Management Solicits Proxies from Shareholders of Neuphoria Therapeutics	CI
11-24	Neuphoria Therapeutics Sends Letter to Stockholders	CI
11-24	Neuphoria Therapeutics Inc. Sends Letter to Stockholders	AQ